DAT在低风险新生儿ABO或RhD不合中的效用
该回顾性队列研究纳入618名≥35周新生儿,评估常规直接抗人球蛋白试验(DAT)在ABO不合及ABO相合/RhD不合新生儿中的临床价值。结果显示,ABO不合组DAT阳性与光疗需求增加相关,但经皮胆红素(TcB)单独预测光疗的AUC达0.887,加入DAT仅提升至0.896;RhD不合组DAT阳性率14.0%但仅1.0%需光疗。结论支持2022年美国儿科学会指南,建议在这类低风险人群中停止常规DAT筛查。
要点
- ABO不合新生儿中,TcB单独预测光疗需求AUC为0.887,加入DAT仅微增至0.896。
- ABO相合/RhD不合新生儿中,14.0% DAT阳性但仅1.0%需光疗,DAT与TcB无相关性。
- 常规DAT在低风险ABO或RhD不合新生儿中预测价值有限,支持停止常规筛查。
核心结论
- 常规DAT筛查对ABO不合新生儿的预测价值在TcB监测之外极小,对仅暴露于被动抗D的RhD不合新生儿无临床效用。
研究设计与样本
- 回顾性队列研究,纳入618名出生后≥35周并接受DAT筛查的新生儿,分为ABO不合组(N=310)和ABO相合/RhD不合组(N=308)。
主要发现
- ABO不合组中DAT阳性与较高TcB及光疗需求增加相关,但TcB单独预测光疗的AUC=0.887,加入DAT后AUC=0.896。
- ABO相合/RhD不合组中14.0%新生儿DAT阳性(归因于被动母体抗D),与TcB无相关性,仅1.0%需光疗。
关键数值与推荐
- ABO不合组:TcB单独预测光疗AUC=0.887,TcB+DAT联合AUC=0.896。
- ABO相合/RhD不合组:DAT阳性率14.0%,光疗需求率1.0%。
临床怎么用
- 对于低风险ABO不合或ABO相合/RhD不合(仅被动抗D)新生儿,可考虑停止常规DAT筛查,以TcB监测为主。
- maternal antibody screening remains essential, and DAT must be performed if maternal screening is incomplete or unavailable.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Routine direct antiglobulin test (DAT) screening in newborns at risk of isoimmune hemolytic disease is a long-standing practice. Advancements in prophylactic care and noninvasive hyperbilirubinemia monitoring warrant reevaluating the value of DAT. We investigated the clinical utility of routine DAT screening for mature newborns with ABO incompatibility and ABO-compatible newborns with RhD incompatibility born to mothers without active alloimmunization. METHODS: We conducted a retrospective cohort study of infants born after 35 weeks or more of gestation undergoing DAT screening. Infants were stratified into ABO-incompatible and ABO-compatible/RhD-incompatible cohorts. Bivariable correlations, logistic regression, and area under the receiver operating characteristic curve (AUC) were used to assess predictors for phototherapy requirements. RESULTS: Among 618 infants included in the analysis, within the ABO-incompatible cohort (N = 310), DAT positivity was associated with higher transcutaneous bilirubin (TcB) and increased phototherapy requirement. However, TcB alone robustly predicted the phototherapy requirement (AUC = 0.887). Incorporating DAT minimally enhanced the predictive capacity (AUC = 0.896). In the ABO-compatible/RhD-incompatible cohort (N = 308), 14.0% of infants had a positive DAT attributed to passive maternal anti-D, showing no correlation with TcB. Only 1.0% of these infants required phototherapy. CONCLUSIONS: Our data showed routine DAT screening provides minimal predictive value beyond TcB monitoring for ABO-incompatible infants and offers no clinical utility for RhD-incompatible infants exposed solely to passive anti-D. These findings validate the 2022 American Academy of Pediatrics guidelines, suggesting that discontinuing routine DAT in these low-risk populations safely optimizes laboratory resources. Importantly, maternal antibody screening remains essential, and DAT must be performed if maternal screening is incomplete or unavailable.
引用
- Tsai TL, Ma T, Nester T, et al. Utility of DAT in Low-Risk Neonates With ABO or RhD Incompatibility. Pediatrics. 2026. PMID: 42642037. doi:10.1542/peds.2026-076989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。